Presentation (CTI)

OBJECTIVES: CIDP is a rare autoimmune disorder characterized by progressive muscle weakness and functional impairment that imposes a significant burden on patients’ HRQoL. Real-world evidence regarding the impact of existing standard treatments for CIDP on patients’ HRQoL remains fragmented. This SLR aimed to assess the impact of current standard treatments on HRQoL in patients with CIDP in real-world settings.
METHODS: Searches were conducted in Embase and Medline databases from inception to October 2025 to identify observational studies published in English that reported HRQoL outcomes in adults with CIDP receiving standard treatments. Database searches were supplemented with hand searching of key conferences and bibliographies of included studies.
RESULTS: Seven studies met the pre-defined eligibility criteria from 830 identified records. All the included studies were from Europe evaluating 488 participants treated with either intravenous or subcutaneous immunoglobulin (IVIg/SCIg), corticosteroids, or plasma exchange. Most of the studies assessed HRQoL using generic tools: short form-36 health survey (SF-36, n=4 studies) and EuroQol 5-dimension questionnaire (EQ-5D, n=2). One study used disease-specific scale i.e. chronic acquired polyneuropathy patient-reported index (CAP-PRI). Studies assessed HRQoL at varied time-points ranging from intermediate (6-12 months, n=3) to long-term duration (24-48 months; n=4). Majority of the studies demonstrated no change/improvement in HRQoL of patients with CIDP as assessed by SF-36 (n=4), EQ-5D (n=1) and CAP-PRI (n=1) scales. Only one study by Cirillo et al., 2019 demonstrated improvement in HRQoL with long-term use of SCIg as assessed by EQ-5D VAS score (mean score [standard deviation, SD] at 24 months: 69.4 [8.4] versus 51.5 [8.1] at baseline; p<0.05 and at 48 months: 86.0 [7.5]; p<0.05 versus 24 months).
CONCLUSIONS: Findings from this SLR highlighted limited, heterogenous real-world evidence assessing the impact of standard treatments on HRQoL. These results underscore the need for novel CIDP treatments that could improve patients’ HRQoL and standardized HRQoL assessment with extended follow-up.